{"name":"Inventiva Pharma","slug":"inventiva-pharma","ticker":"","exchange":"","domain":"inventivapharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTFM3c0Z3TmRzWENhVVl4eGlzN3pqVjRObXVudFhjNnpFWnpEYXVfVkNyaGYzRWY5RlQxamQ5Mng1eFlUYklISjlraWFhdmZKWTE5Y2hKNHppX1U4SnNIYmhCV1hwVENtMFlrSmpwZ2REbklRN3hzUXRvTUYzcElleEJsM2hjRG93Q2FmTHc5NzlGNF9OSFVlRDd5WW9pSjc0SEVieEhPRmJqV1k?oc=5","date":"2026-02-19","type":"pipeline","source":"The Business Journals","summary":"Rezdiffra nears blockbuster status as Madrigal turns a 'graveyard' into a goldmine - The Business Journals","headline":"Rezdiffra nears blockbuster status as Madrigal turns a 'graveyard' into a goldmine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNejRyczN1bWJtSFhpR1pFMnhlX2MtNEhicGVKQk1tVnpTNXNkZWlDaHgxLXMwZXpTSFlSSEM5ckwwVmhWZTF3LWJlTnNhWmd4Yjc0bTNJX09WbURsaURTdUxQSjdkSzJKUWpRQTZlNXpfVEpqTXhEZG9fNmlSOU1ZS1ZIOWhMRkdEelJuQ3NjcEF5d2Zrckd1N0l3?oc=5","date":"2026-02-04","type":"pipeline","source":"Yahoo Finance UK","summary":"Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Yahoo Finance UK","headline":"Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOSEFyNFZockdFUGNnd280U05haDlHd1dXRGtMTXBtSXVUNGJLM250V1l6VmE4RzZKVnR0SFZubms1c2YxczNYS3Q4Y2EzRHFUMDhzejJHR2pWTWx0OFFtbE05NXRXaFRSS25CMG5ydWZYbkUxQTI4SWdLRS1nM2Y1Y1RIX1dMZnk4NzNYLWdsWFh0TUdIRlMwQTRaWllPdw?oc=5","date":"2026-01-28","type":"pipeline","source":"Global Banking & Finance Review®","summary":"Inventiva's Stock Surge Reflects Growing Investor Optimism - Global Banking & Finance Review®","headline":"Inventiva's Stock Surge Reflects Growing Investor Optimism - Global Banking & Finance Review®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNd05JcXpzN00zWkF1eTViWEdLRlJjaElhQmtseS00dXFLOTVERTlpaThMbnUtUUc5VV82MW1iTXBaWVJCcnJ4UlFSNjVFbXhaN0oydUk1dlQ3OW1WZTk3Njdnblh0UkJjNDlMTFlPME5hY3F3M2dPM21udF9XTWxNeXp6NGM5bGF2WDFlZUV0cHdRYnVvbmRXcWYzaTNFSEEyZmRRRmt6aDJHN0V6NDFBaUZrWDU?oc=5","date":"2025-12-18","type":"trial","source":"Bloomberg.com","summary":"Five European Biotech Stocks Face Pivotal Trial Results in 2026 - Bloomberg.com","headline":"Five European Biotech Stocks Face Pivotal Trial Results in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQLWR2a2J0OFFFNjJqMlQ5TXo2Y1ZCalo5dmk5RnYyWnFMTWxPVkw2UnhxWmhiVklsV3hDZFRJTHptLTFNSEl6RDA0RGZvb2tpS1Y5Tk52ekpETVd1Y1RRRHVGWkphYk9OcHJDNWdGTUtjeFNnbE9rbm1wNDdYUDMtMWVqTDh1VlpENWVMZTFaQ2JTaTFVUmpuZW9wTXBxREtneUt6cWZxc2lDV1JqN011dFNzWkFacnV3dkV5ZTA1YXJZWkxDT2xsNGVkVmlGWDBtb0hJeTgtVHBfOUczSHc?oc=5","date":"2025-10-14","type":"pipeline","source":"investorsinhealthcare.com","summary":"France: Inventiva appoints Andrew Obenshain as CEO to fuel next step in growth plans - investorsinhealthcare.com","headline":"France: Inventiva appoints Andrew Obenshain as CEO to fuel next step in growth plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNTWxEZEh6enVZcDM0TkNBWVBfallWSUhsMlg4OU1NUFdGLXNHd3Ytd3NxM3RUOGFuMW5ER09SNTZTX2pCeDM5VGZmd01wZ3k5NVlJMEJYWnE2X1E3NWM2LXJnWmhXN3VCWFZQTFRzM0l1dHBNU0VqOTQwSmYwLVcxeVZJdlFYWGsxOWVpdlpucWxMSFNITTl0Y0lYRTZGOE1lUGlyQnFnSWxCQWE5WE1vRnZEalZ2cGxXMHVUUDhpOW9BdkdCdHc3R2ZmNnVVb3M?oc=5","date":"2025-10-01","type":"pipeline","source":"GlobeNewswire","summary":"Inventiva Appoints Andrew Obenshain as Chief Executive Officer - GlobeNewswire","headline":"Inventiva Appoints Andrew Obenshain as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPeDFJQTZ4c3RNNzA5RXN5R01TMU03c1U4X3BBamRCWEYwaFlGNFdWTzR4ZVJFMFRNaGVZV2ZLN2tzZDRZRUlIb1pxLVZwMFBOeGhWenFhTjNFQmtzTnVYdWRtN3RoZ09VekhzVExjaFBmR3pUM1lHMmJMQ1U5cVR0X3FoNkY?oc=5","date":"2025-02-11","type":"pipeline","source":"Fierce Biotech","summary":"Inventiva lays off 50% of staff to go all-in on MASH drug - Fierce Biotech","headline":"Inventiva lays off 50% of staff to go all-in on MASH drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE43TDRyak94VEstemVIV2pJaG8xdzdhTjloVzNEeDVZbUpBVnVaVVMzLUdKQ29WbmVDbS1GOXp1SjhnWWRsOFZ3TTRkTUstTGJOdUFz?oc=5","date":"2025-02-11","type":"pipeline","source":"FirstWord Pharma","summary":"Third Harmonic, Inventiva cut their workforces in half - FirstWord Pharma","headline":"Third Harmonic, Inventiva cut their workforces in half","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOSkRNQnZzM2ZvWEduS1FGWk9lOXh1MXo2Tmo5Zk1sRmZtWjNROUVaM1VJTGwwYVBUNXp2eGFhblhTSXNTTWFLazRGaUFaZ1NzNGU5QmI5bm92S3pWbTM0LVNHTUFlM2ZFQlRfTjNRaF9xQkN6cUp6SlRTMkNSZ0RsQkRn?oc=5","date":"2024-11-18","type":"pipeline","source":"Pharma Voice","summary":"The first MASH drug could open the door for others — including GLP-1s - Pharma Voice","headline":"The first MASH drug could open the door for others — including GLP-1s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZXRDOGxsRTdUN2djT3dOWVZwMmFzZ0labTRueHdGZmt2SXdydzAxR01ScTZac0ljV2xqSEdOTDZjb1BTdktjX2c3WUJLX2VzS2hxVzJ6WTVCVEdqcUZPYUNpRzV0UldEUlBCa0N1RkYyVHlEeWFwc0VJMWJMUW5JNG55SlE4QmpwOUhlOXJyRzBIckJXQVBUSHJJc3Zhb1ZhNE5YVW9OUkdiazRo?oc=5","date":"2024-10-14","type":"pipeline","source":"Pharmaceutical Technology","summary":"Inventiva secures up to $380m for MASH treatment lanifibranor - Pharmaceutical Technology","headline":"Inventiva secures up to $380m for MASH treatment lanifibranor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE93QXJQZ19RSnBIdjVOUm1nNWN1WWc1a3ZtRFZrZ05vbmFlVE5UcmluRmVXbF92SkQ1U0lOY3E1R3VoMmNpVHpPQzV1azNPLXpDYk52UEJHbU9ONjBpcVhCTG5TenU5cVMyUEZDZEc5OA?oc=5","date":"2024-07-06","type":"pipeline","source":"The Pharma Letter","summary":"Inventiva Pharma - The Pharma Letter","headline":"Inventiva Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPWE5sR1dWZW1pY011M2V3bFRYclpIbThsNW9WanluMXN4UGhVZVRnZ1RkVWNIbmtCdk5rUnJGZFFPZXhDZ08yb3ZVeXZlQ25iTTI0VVR1UE5wcnlBTjEtb3AwWEYxTEhzTjN1VUF1NHc2NlA4Z19aanhwZ2xZQVBMNjlld0twajBLWjQ5YU1Va2MtNmRNVFIzREc0aTRDUGNHR1AtNjhaZTdkdktDWjZVX2Y4VVRkcDJ5?oc=5","date":"2024-02-16","type":"trial","source":"Clinical Trials Arena","summary":"Inventiva halt recruitment for Phase III NASH trial following adverse event - Clinical Trials Arena","headline":"Inventiva halt recruitment for Phase III NASH trial following adverse event","sentiment":"negative"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}